Technology

Rethinking Protein Expression from the Ground Up

Roke’s technology unlocks new applications using novel E. coli strains that operate beyond traditional growth-associated boundaries.

Our systems engineering approach enables plug-and-play protein expression -delivering customized solutions on unprecedented timelines.

Demonstrated Performance

Slide Background

Scale Up Without Process Development

From prototyping to production—no tuning, no delays. Our unified bioprocess expresses diverse proteins with high reproducibility across formats, minimizing development time and cost.

Backed by Data

-Consistent high titers from microtiter plates to bioreactors—no reoptimization required.
-Autoinducible system triggered by nutrient depletion—no inducers, no manual tuning.
-Standardized workflow supports diverse protein expression with reproducible results at any scale.

READ OUR VHH PUBLICATION FOR MORE DETAILS

Menacho-Melgar R, et. al. Biotechnol Bioeng. 2020 Sep;117(9):2715-2727. https://pubmed.ncbi.nlm.nih.gov/32441815/

Slide Background

Lower Protein Purification Costs

Cell-programmed downstream enables In Bioreactor cell lysis and purification, lowering both COGS and CapEx.

Our engineered strains integrates autolysis and heat-based enrichment steps directly into the bioreactor workflow. This eliminates the need for costly chromatography steps and simplifies downstream processing without compromising quality or performance.

Backed by Data

-One-step research-grade protein purification
-Achieve >60% lower COGS and CapEx

-One-step research-grade protein purification

-Achieve >60% lower COGS and CapEx

READ OUR PUBLICATIONS FOR MORE DETAILS

Menacho-Melgar R, et. al. Biotechnol Bioeng. 2020 Sep;117(9):2852-2860. https://pubmed.ncbi.nlm.nih.gov/32441815/
Decker JS, et. al. Biochem Eng J. 2022 Apr;181:108403. https://pubmed.ncbi.nlm.nih.gov/35308834/
Menacho-Melgar R. et. al. BioRxiv Preprint. https://www.biorxiv.org/content/10.1101/2021.09.25.461774v1

Slide Background

Engineered for Difficult Proteins

Robust, ready-to-use solutions for challenging proteins: disulfide-bonds, unstable, and beyond.

Backed by Data

-Industry-leading E. coli nanobody expression platform, validated across single and tandem VHHs with titers up to 6 g/L.
-Over 10x expression improvement on degradation-prone proteins (including a ~300 kDa protein).

READ OUR VHH PUBLICATION FOR MORE DETAILS

Hennigan JN, et. al. Metab Eng. 2024 Sep;85:116-130. https://pubmed.ncbi.nlm.nih.gov/39059674/

Let’s Build Better Bioprocesses Together

Ready to evaluate the platform or explore a licensing opportunity?